Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Secreted frizzled-related protein 4 (SFRP4)
- Target
- SFRP4
- Molecular classification
- Wnt signaling antagonist/modulator, Secreted protein, Receptor-interacting molecule, Phosphaturic factor, Other (adipokine)
01
Overview
Secreted frizzled-related protein 4 (SFRP4) is a secreted glycoprotein belonging to the SFRP family, characterized by a cysteine-rich domain homologous to the Wnt-binding site of Frizzled receptors. SFRP4 acts primarily as a soluble antagonist of Wnt signaling, modulating cell proliferation, apoptosis, and differentiation in various tissues. Its clinical significance includes roles in tumorigenesis (serving as an oncogenic or tumor suppressive factor depending on context), regulation of insulin secretion with implications for diabetes, effects on bone remodeling, and immune microenvironment modulation. Elevated expression of SFRP4 can serve as a prognostic biomarker in several cancers and may represent a therapeutic target for immunomodulation and chemosensitization.
- Other names
- SFRP4sFRP-4FRPHEFRP-4FRZB-2Frizzled protein, human endometriumPYL
02
Mechanism of action
Antagonism or modulation of Wnt signaling pathway (which controls cell proliferation, differentiation, and apoptosis); Modulation of immune cell infiltration and chemokine production; Sensitization of cancer stem cells to chemotherapy
03
Biological functions
Modulation of Wnt signalingRegulation of cell proliferation and differentiationRegulation of apoptosisControl of bone morphogenesis and remodelingRegulation of insulin secretion and glucose homeostasisModulation of immune response and tumor microenvironment
04
Disease associations
Cancer (pancreatic, colorectal, prostate, gastric, ovarian, mesothelioma, head and neck, glioblastoma)Metabolic disease (Type 2 diabetes)Bone disorders (Pyle disease, osteomalacia)Renal disease (polycystic kidney disease, phosphate metabolism disturbance)
05
Safety considerations
No major safety concerns reported for targeting SFRP4 itself, but modulation of Wnt signaling carries theoretical risks of disturbing normal tissue homeostasis, bone formation, and metabolic balancePotential off-target effects relating to bone fragility (as evidenced by Pyle disease) and disturbance of insulin secretion
06
Interacting drugs
There are no major approved drugs that directly target SFRP4, but SFRP4 is under investigation as a potential target in cancer immunotherapy and chemosensitization. No FDA-approved drugs directly interact with SFRP4.
07
Biomarkers
SFRP4 protein or mRNA levels for prognosis in pancreatic, colorectal, and gastric cancerSerum SFRP4 as early biomarker in type 2 diabetes
Beyond the preview
Go deeper on Secreted frizzled-related protein 4 (SFRP4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Secreted frizzled-related protein 4 (SFRP4).